Cell Source Inc. (CLCS) 1.4000 $CLCS
Cell Source to Present at the Roth Capital Conference in Dana Point, CA on March 10, 2015
ACCESSWIRE - Mon Mar 09, 10:22PM CDT
TEL AVIV, ISRAEL / ACCESSWIRE / March 9, 2015 / Cell Source, Inc. (OTCQB:CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at the Roth Conference on Tuesday, March 10, 2015 at 5:30pm in Dana Point, California.
Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials
PR Newswire - Thu Nov 13, 3:00AM CST
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source" an immunotherapy and regenerative medicine company, announced today its Megadose Drug Combination has been cleared for human clinical trials in Italy. Cell Source's proprietary Megadose Drug Combination is expected to increase bone marrow transplantation (BMT) success and survival. By combining an established cell therapy with U.S. Food and Drug Administration (FDA) approved drugs, Megadose Drug Combination, based on preclinical results to date, may have the potential to enable an improvement in the effectiveness and safety of use of mismatched BMT. BMT is most often used for the treatment of blood cancers and is currently reserved mostly for patients with life threatening diseases, due to complications including transplant rejection. Should BMT become safer, the procedure's use may well be expanded beyond cancer to other indications including genetic and autoimmune disease.
Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 60.23 (+0.45), SHPG: 254.45 (+3.99)
Cell Source to Present at the FireRock Conference and the Life Sciences Summit in New York City on October 28th and 29th, 2014
PR Newswire - Wed Oct 08, 6:00AM CDT
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source" an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at two upcoming conferences in New York City during the month of October.
Cell Source to Present at Rodman & Renshaw Global Investment Conference in New York City on September 10, 2014
PR Newswire - Wed Sep 03, 12:52PM CDT
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source" an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at the Rodman & Renshaw 16th Annual Global Investment Conference which will take place at the New York Palace Hotel in New York City on September 8th through 10th, 2014. Mr. Shimrat is scheduled to present at 9.35 am on Wednesday, September 10th.
Cell Source Inc. Announces Acquisition and $3.6 Million Private Placement to Advance Novel Cancer Therapies
PR Newswire - Tue Jul 01, 12:30PM CDT
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source" today announced the successful acquisition (the "Acquisition", through a share exchange agreement, of all of the outstanding shares of Cell Source (Israel) Ltd., a pre-clinical cell therapy development company with a focus on the facilitation of safer and more accessible bone marrow and organ transplants and effective treatment of blood cell cancers (e.g., leukemia, lymphoma). Prior to the Acquisition, Cell Source Ltd. completed a private placement consisting of approximately 4.8 million units of its securities, for total gross proceeds of approximately $3.6 million. Each unit consisted of one share of common stock and one common stock purchase warrant. Sichenzia Ross Friedman Ference LLP (www.SRFF.com) acted as legal counsel to Cell Source (Israel) Ltd. in the private placement and Acquisition.
Cell Source to Present at the Roth Capital Conference in Dana Point, CA on March 10, 2015
ACCESSWIRE - Mon Mar 09, 10:22PM CDT
TEL AVIV, ISRAEL / ACCESSWIRE / March 9, 2015 / Cell Source, Inc. (OTCQB:CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at the Roth Conference on Tuesday, March 10, 2015 at 5:30pm in Dana Point, California. Cell Source's Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials
PR Newswire - Thu Nov 13, 3:00AM CST
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its Megadose Drug Combination has been cleared for human clinical trials in Italy. Cell Source's proprietary Megadose Drug Combination is expected to increase bone marrow transplantation (BMT) success and survival. By combining an established cell therapy with U.S. Food and Drug Administration (FDA) approved drugs, Megadose Drug Combination, based on preclinical results to date, may have the potential to enable an improvement in the effectiveness and safety of use of mismatched BMT. BMT is most often used for the treatment of blood cancers and is currently reserved mostly for patients with life threatening diseases, due to complications including transplant rejection. Should BMT become safer, the procedure's use may well be expanded beyond cancer to other indications including genetic and autoimmune disease. Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 60.23 (+0.45), SHPG: 254.45 (+3.99)
Cell Source to Present at the FireRock Conference and the Life Sciences Summit in New York City on October 28th and 29th, 2014
PR Newswire - Wed Oct 08, 6:00AM CDT
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at two upcoming conferences in New York City during the month of October. Cell Source to Present at Rodman & Renshaw Global Investment Conference in New York City on September 10, 2014
PR Newswire - Wed Sep 03, 12:52PM CDT
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source"
an immunotherapy and regenerative medicine company, announced today its President and CEO, Itamar Shimrat, will present at the Rodman & Renshaw 16th Annual Global Investment Conference which will take place at the New York Palace Hotel in New York City on September 8th through 10th, 2014. Mr. Shimrat is scheduled to present at 9.35 am on Wednesday, September 10th. Cell Source Inc. Announces Acquisition and $3.6 Million Private Placement to Advance Novel Cancer Therapies
PR Newswire - Tue Jul 01, 12:30PM CDT
Cell Source, Inc. (OTCQB: CLCS) ("Cell Source"
today announced the successful acquisition (the "Acquisition", through a share exchange agreement, of all of the outstanding shares of Cell Source (Israel) Ltd., a pre-clinical cell therapy development company with a focus on the facilitation of safer and more accessible bone marrow and organ transplants and effective treatment of blood cell cancers (e.g., leukemia, lymphoma). Prior to the Acquisition, Cell Source Ltd. completed a private placement consisting of approximately 4.8 million units of its securities, for total gross proceeds of approximately $3.6 million. Each unit consisted of one share of common stock and one common stock purchase warrant. Sichenzia Ross Friedman Ference LLP (www.SRFF.com) acted as legal counsel to Cell Source (Israel) Ltd. in the private placement and Acquisition. 
